Japan’s Eisai’s New Alzheimer’s Drug Found Effective

From Jiji

September 29 2022

TOKYO. – Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc. said Wednesday an Alzheimer’s drug they are jointly developing has been found effective in slowing the deterioration of symptoms in a late-stage clinical trial.

Eisai plans to apply for regulatory approval of the drug, lecanemab, in Japan, the United States and Europe by the end of next March.